Chandra Kirana

Dr Chandra Kirana

Senior Research Officer

Adelaide Medical School

Faculty of Health and Medical Sciences


My Research :
Dr Chandra Kirana's research interest focus on finding biomarkers for bowel cancer patients using proteomic approaches. Almost 90% of bowel cancer patients died from metastatic dissemination mostly to the liver. Protein biomarkers are urgently required to support current methodologies to improve accuracy in stratifying patients into low and high risk of metastasis so that accurate disease management will be given to the patients to increase survival. In addition, she is also interested in using the concept of "seed and soil" to understand the mechanism of metastatic dissemination of colorectal cancer to the liver. Her work equipped with a large number of samples from bowel cancer patients completed with clinical parameters of the patients and the histology of tumours. She also has experience in isolation and identification of bio-active compounds from medicinal plants using various chromatographic and spectrophotometric techniques. Her previous work involved using small animals to assess efficacy of active compounds isolated from medicinal plants including AOM-induced colon cancer and DSS-induced inflammatory bowel disease model study.

Collaborations:
Clinicians at The Queen Elizabeth Hospital and Royal Adelaide Hospital
Mr John Keating, Wellington Hospital, Wellington, New Zealand
Professor Richard Stubbs, P3 Research, Wellington, New Zealand
Dr Lifeng Peng, Centre for Biodiscovery, School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand
Dr Andrea Bubendorfer, Callaghan Innovation, New Zealand's Innovation Agency, Wellington, New Zealand

Consumer Engagement:
Cancer Voices SA

    Expand
  • Journals

    Year Citation
    2019 Kirana, C., Peng, L., Miller, R., Keating, J., Glenn, C., Shi, H., . . . Stubbs, R. (2019). Combination of laser microdissection, 2D-DIGE and MALDI-TOF MS to identify protein biomarkers to predict colorectal cancer spread. Clinical Proteomics, 16(1), 13 pages.
    DOI
    2017 Miljkovic, D., Ou, J., Kirana, C., Hulse, K., Hauben, E., Psaltis, A., . . . Vreugde, S. (2017). Discordant frequencies of tissue-resident and circulating CD180-negative B cells in chronic rhinosinusitis. International Forum of Allergy and Rhinology, 7(6), 609-614.
    DOI Scopus2 WoS2 Europe PMC2
    2017 Kirana, C., Ruszkiewicz, A., Stubbs, R., Hardingham, J., Hewett, P., Maddern, G., & Hauben, E. (2017). Soluble HLA-G is a differential prognostic marker in sequential colorectal cancer disease stages. International Journal of Cancer, 140(11), 2577-2586.
    DOI Scopus4 WoS4 Europe PMC1
    2013 Shi, H., Hayes, M., Kirana, C., Miller, R., Keating, J., & Stubbs, R. (2013). Overexpression of aminoacylase 1 is associated with colorectal cancer progression. Human Pathology, 44(6), 1089-1097.
    DOI Scopus6 WoS5 Europe PMC6
    2012 Kirana, C., Shi, H., Laing, E., Hood, K., Miller, R., Bethwaite, P., . . . Stubbs, R. (2012). Cathepsin D expression in colorectal cancer: from proteomic discovery through validation using western blotting, immunohistochemistry, and tissue microarrays. International journal of proteomics, 2012, 1-11.
    DOI Europe PMC12
    2012 Shi, H., Hayes, M., Kirana, C., Miller, R., Keating, J., MacArtney-Coxson, D., & Stubbs, R. (2012). TUFM is a potential new prognostic indicator for colorectal carcinoma. Pathology, 44(6), 506-512.
    DOI Scopus15 WoS13 Europe PMC10
    2009 Kirana, C., Ward, T., Jordan, T., Rawson, P., Royds, J., Shi, H., . . . Hood, K. (2009). Compatibility of toluidine blue with laser microdissection and saturation labeling DIGE. Proteomics, 9(2), 485-490.
    DOI Scopus12 WoS11 Europe PMC9
    2007 Kirana, C., Jones, G., Record, I., & McIntosh, G. (2007). Anticancer properties of panduratin A isolated from Boesenbergia pandurata (Zingiberaceae). Journal of Natural Medicines, 61(2), 131-137.
    DOI Scopus34 WoS25
    2005 Kirana, C., Rogers, P., Bennett, L., Abeywardena, M., & Patten, G. (2005). Naturally derived micelles for rapid in vitro screening of potential cholesterol-lowering bioactives. Journal of Agricultural and Food Chemistry, 53(11), 4623-4627.
    DOI Scopus39 WoS29 Europe PMC23
    2003 Kirana, C., McIntosh, G., Record, I., & Jones, G. (2003). Antitumor activity of extract of Zingiber aromaticum and its bioactive sesquiterpenoid zerumbone. Nutrition and Cancer-An International Journal, 45(2), 218-225.
    DOI Scopus88 WoS73 Europe PMC47
    2003 Kirana, C., Record, I., McIntosh, G., & Jones, G. (2003). Screening for antitumor activity of 11 species of Indonesian Zingiberaceae using human MCF-7 and HT-29 cancer cells. Pharmaceutical Biology, 41(4), 271-276.
    DOI Scopus34 WoS22
  • Conference Papers

    Year Citation
    2018 Kirana, C. (2018). Communication between mothers and children about environmental issues (a study about the role of mothers to educate their children on keeping a clean environment). In E3S Web of Conferences Vol. 74 (pp. 1-7). Jakarta.
    DOI
    2005 Kirana, C., Rogers, P., Bennett, L., Abeywardena, M., & Patten, G. (2005). Rapid screening for potential cholesterol-lowering peptides using naturally derived micelle preparation. In Australian Journal of Dairy Technology Vol. 60 (pp. 163-166). Adelaide, AUSTRALIA: DAIRY INDUSTRY ASSOC AUSTRALIA.
    Scopus6 WoS3
    Expand
  • Committee Memberships

    Date Role Committee Institution Country
    2017 - ongoing Member TQEH Strategic Research Direction The Queen Elizabeth Hospital - Basil Hetzel Research Institute Australia
    2016 - ongoing Member The Institute (BHI) Policy Committee Basil Hetzel Institute Australia
    2015 - ongoing Co-Chair The Institute (Basil Hetzel Institute) Management Committee Basil Hetzel Research Institute Australia
  • Position: Senior Research Officer
  • Phone: 82227426
  • Email: chandra.kirana@adelaide.edu.au
  • Campus: North Terrace
  • Building: TQEH - Basil Hetzel Institute, floor 1
  • Org Unit: Adelaide Medical School

Connect With Me
External Profiles